Infectious disease and surveillance, Thematic Committee

Dr. Janak Koirala

Dr. Janak Koiral is a professor of medicine and infectious disease at Patan academy of Health Sciences and clinical research consultant at Nepal Health Research Council. Additionally, he serves as professor in Emeritus and former division Chief of infectious diseases at Southern Illinois University School of Medicine. With over 2 decades of experience in clinical research, he has authored over 600 peer reviews, has scientific Publication in International Journal and also presented on several national and international forums. He has led multiple study in Nepal as Country PI including WHO solidarity plus child for treatment of COVID-19. Dr. Koirala is fellow of American College of Physician and a fellow of Infectious Disease Society of America. He currently serves as executive member of the Global Health Community of Infectious Disease, Society of America.

Publications:

  1. Disseminated Cysticercosis with Tongue Involvement: A Rare Case Report from Nepal Authors
  2. Coronavirus Disease (COVID-19) Mortality and its Associated Factors in Nepal – A Cross-sectional Study
  3. Open Forum Infectious Diseases Experience of Treating COVID-19 With Remdesivir and Convalescent Plasma in a Resource-Limited Setting: A Prospective, Observational Study
  4. Case Report: Intrahepatic cholestasis: a diagnostic dilemma
  5. 1779. An Assessment of Antibiotic Treatment Guideline Adherence for Common Infections in a Tertiary Care Hospital with an Established Antimicrobial Stewardship Program in Kathmandu, Nepal
  6. Efficacy of Favipiravir in treatment of mild & moderate COVID-19 infection in Nepal: a multi-center, randomized, open-labelled, phase III clinical trial
  7. Nepal Paediatric Society Guideline for use of Antibiotics in Critically ill Children in the Pediatric Intensive Care Unit
  8. Experience of Treating COVID-19 With Remdesivir and Convalescent Plasma in a Resource-Limited Setting: A Prospective, Observational Study
  9. Treatment of COVID-19 in Hospitalized Patients with Remdesivir, Convalescent Plasma or Both in a Resource Limited Setting: A Prospective Study